期刊文献+

慢病毒介导的血友病B基因在离体细胞中的表达 被引量:3

In vitro expression of hemophilia B gene mediated by lentivirus
原文传递
导出
摘要 目的构建泛醌肩动子(PUB)驱动的携带犬凝血因子Ⅸ(cFⅨ)基因的慢病毒三质粒表达载体,将其包装成病毒后,观察是否能在体外获得有效的cFⅨ表达。方法采用改良的磷酸钙沉淀法将包装质粒ANRF、包膜蛋白质粒VSV—G和构建的重组转移质粒PTK164共转染293T包装细胞产生慢病毒颗粒,病毒以MOI3:1比例感染培养的第三代骨髓基质细胞和293T细胞,用一期法测定细胞培养上清中cFⅨ活性。结果体外成功培养出骨髓基质细胞,经病毒感染后的骨髓基质细胞和293T细胞均能表达FIX因子,活性分别为(26.30±2.10)%和(19.70±1.53)%,与对照组[(1.00±0.05)%]比较,差异有统计学意义。结论成功构建PUB启动子驱动的cFⅨ基因的三质粒慢病毒表达载体,包装成病毒颗粒后成功转染至培养的骨髓基质细胞和293T细胞。 Objective To construct a three pLasmids LentiviraL vector containing canine coagulation factor Ⅸ (cFⅨ) gene with ubiquinone promoter(PUB) and observe the expression of cFⅨ gene. Methods Lentivirus was generated by transient three-plasmid transfection, nameLy, the VSV-G envelope expression cassette, the ANRF packaging plasmid and the PTK 164 plasmid. Viral particles were used to infect the target cell, third passage mesenchymal stem cells (MSCs) and 293T cell respectively at MOI 3: 1. The cFIⅨ activity was detected in cultured cells with one-stage clotting assay. Results The MSCs were obtained in vitro. The lentivirus infected MSCs and 293T cells all expressed the active factor IX with the activity of (26.30 ± 2.10)% and ( 19.70 ± 1.53)%, respectively, which are significantly higher than that of control ( 1.00 ± 0. 05) %. Conclusions The Lentiviral vector of three plasmids with ubiquinone promoter(PUB) was constructed and can transfect the MSCs and 293T cells.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第9期583-586,共4页 Chinese Journal of Hematology
基金 国家自然科学基金(30370606)
关键词 慢病毒 血友病B 骨髓基质细胞 基因疗法 Lentivirus HemaphiLia B Mesenehymal stem cell Gene therapy
  • 相关文献

参考文献12

  • 1Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet, 2003,361 : 1801-1809.
  • 2Castaldo G, Nardiello P, Bellitti F, et al. Haemophilia B: from molecular diagnosis to gene therapy. Clin Chem Lab Med, 2003, 41:445 -451.
  • 3鄂征.组织培养和分子生物学技术.北京:北京出版社,2001:82-83.
  • 4Waddington SN, Buckley SK, Nivsarkar M, et al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood, 2003, 101 : 1359- 1366.
  • 5Arruda VR, Stedman H, Nichols TC, et al. Regional intravascular delivery of AAV-2-F. IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood, 2005, 105:3458-3464.
  • 6Ljung RC. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost, 1999, 82:525-530.
  • 7High K. Gene transfer as an approach to treating hemophilia. Circ Res, 2001, 88: 137-144.
  • 8Friedenstein A J, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol, 1974, 2:83-92.
  • 9Trubiani O, Di Primio R, Traini T, et al. Morphological and cytofluorimetric analysis of adult mesenchymal stem cells expanded ex vivo from periodontal ligament. Int J Immunopathol Pharmacol, 2005, 18:213-221.
  • 10Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene lherapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood, 2003, 101:3924-3932.

同被引文献37

  • 1Themis M,May D,Coutelle C,et al.Mutational effects of retrovirus insertion on the genome of V79 cells by an attenuated retrovirus vector:implications for gene therapy.Gene Ther,2003;10(19):1703.
  • 2Mingozzi F,Chen Y,Murphy SL,et al.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.Mol Ther,2012;20(7):1410-1416.
  • 3Mingozzi F,Chen Y,Edmonson SC,et al.Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.Gene Ther,2013;20(4):417-424.
  • 4Matrai J,Chuah MK,Vanden Driessche T,et al.Recent advances in lentiviral vector development and applications.Mol Ther,2010;18(3):477-490.
  • 5Matsui H,Hegadorn C,Ozelo M,et al.A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia A.Mol Ther,2011;19(4):723-730.
  • 6Matsui H,Shibata M,Brown B,et al.A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+T regulatory cells.Blood,2009;114(3):677-685.
  • 7Matrai J,Cantore A,Bartholomae CC,et al.Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigenspecific tolerance in mice with 1ow genotoxic risk.Hepatology,2011;53(5):1696-1707.
  • 8Liu Q,Muruve DA,et al.Molecular basis of the inflammatory response to adenovirus vectors.Gene Ther,2003;10(11):935-940.
  • 9Mays LE,Wilson JM.The complex and evolving story of T cell activation to AAV vector-encoded transgene products.Mol Ther,2011;19(1):16-27.
  • 10Wang L,Wang H,Bell P,et al.Systematic evaluation of AAV vectors for liver directed gene transfer in murine models.Mol Ther,2010;18(1):118-125.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部